CNEY Regains Compliance with Nasdaq Minimum Bid Price Requirement
The Company's Class A ordinary shares will continue to trade in The Nasdaq Capital Market under the ticker "CNEY."
About CN Energy Group. Inc.
With patented proprietary bioengineering and physiochemical technologies, the Company has pioneered and specialized in producing high-quality recyclable activated carbon from raw carbon materials, converting harmful wastes into a valuable product and delivering significant financial, economic, environmental, and ecological benefits. The Company's products and services have been widely used by food and beverage producers, industrial and pharmaceutical manufacturers, as well as environmental protection enterprises. CNEY also develops and provides customizable robotics products, automation tools, and related software solutions for small and medium-sized industrial, logistics, and service businesses in
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the
These statements are subject to risks and uncertainties, including those described under "Risk Factors" in the Company's filings with the Securities and Exchange Commission, and actual results may differ materially.
Forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update them, except as required by law. Information on the Company's website or social media is not incorporated by reference into this press release.
View original content:https://www.prnewswire.com/news-releases/cney-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302706491.html
SOURCE CN Energy Group. Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Graphic Design Software for Print and Production Work (2026): CorelDRAW Recognized for Print-Friendly, Production-Ready Workflows by Better Business Advice
- Greenberg Traurig's Friederike Görgens Named Law360 Rising Star
- RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share